{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:46:27Z","timestamp":1793339187843,"version":"4.5.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s10741-022-10220-2","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T14:08:05Z","timestamp":1645193285000},"page":"1973-1990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-7055","authenticated-orcid":false,"given":"Surasak","family":"Wichaiyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakkawee","family":"Saengklub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"issue":"22","key":"10220_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, Investigators E-RO (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"4","key":"10220_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Investigators D-T (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"7","key":"10220_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, Group CPC","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, Group CPC (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"15","key":"10220_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Bohm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, Investigators EM-RT (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"issue":"16","key":"10220_CR5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pina IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, Investigators EM-PT (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"issue":"21","key":"10220_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM, Committees D-HT, Investigators, (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"issue":"36","key":"10220_CR7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, Group ESCSD","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, Group ESCSD (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"10220_CR8","doi-asserted-by":"crossref","unstructured":"Scheen AJ (2018) Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 122(10):1439\u20131459","DOI":"10.1161\/CIRCRESAHA.117.311588"},{"issue":"1","key":"10220_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacbts.2018.11.010","volume":"4","author":"KA Connelly","year":"2019","unstructured":"Connelly KA, Zhang Y, Visram A, Advani A, Batchu SN, Desjardins JF, Thai K, Gilbert RE (2019) Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction. JACC Basic Transl Sci 4(1):27\u201337. https:\/\/doi.org\/10.1016\/j.jacbts.2018.11.010","journal-title":"JACC Basic Transl Sci"},{"issue":"7","key":"10220_CR10","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E (2016) CV Protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care 39(7):1108\u20131114. https:\/\/doi.org\/10.2337\/dc16-0330","journal-title":"Diabetes Care"},{"issue":"7","key":"10220_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR (2016) Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis Diabetes Care 39(7):1115\u20131122. https:\/\/doi.org\/10.2337\/dc16-0542","journal-title":"A unifying hypothesis Diabetes Care"},{"issue":"8","key":"10220_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jchf.2021.05.019","volume":"9","author":"M Packer","year":"2021","unstructured":"Packer M (2021) Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes. JACC Heart Fail 9(8):535\u2013549. https:\/\/doi.org\/10.1016\/j.jchf.2021.05.019","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10220_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ (2017) Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits. Diabetologia 60(3):568\u2013573. https:\/\/doi.org\/10.1007\/s00125-016-4134-x","journal-title":"Diabetologia"},{"issue":"3","key":"10220_CR14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia 61(3):722\u2013726. https:\/\/doi.org\/10.1007\/s00125-017-4509-7","journal-title":"Diabetologia"},{"issue":"16","key":"10220_CR15","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","volume":"136","author":"M Packer","year":"2017","unstructured":"Packer M (2017) Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 136(16):1548\u20131559. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030418","journal-title":"Circulation"},{"issue":"7","key":"10220_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jacbts.2019.10.005","volume":"4","author":"S Jun","year":"2019","unstructured":"Jun S, Aon MA, Paolocci N (2019) Empagliflozin and HFrEF: known and possible benefits of NHE1 inhibition. JACC Basic Transl Sci 4(7):841\u2013844. https:\/\/doi.org\/10.1016\/j.jacbts.2019.10.005","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"10220_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/cvr\/cvx149","volume":"114","author":"E Bertero","year":"2018","unstructured":"Bertero E, Prates Roma L, Ameri P, Maack C (2018) Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res 114(1):12\u201318. https:\/\/doi.org\/10.1093\/cvr\/cvx149","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10220_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cardiores.2004.09.024","volume":"65","author":"A Baartscheer","year":"2005","unstructured":"Baartscheer A, Schumacher CA, van Borren MM, Belterman CN, Coronel R, Opthof T, Fiolet JW (2005) Chronic inhibition of Na+\/H+-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure. Cardiovasc Res 65(1):83\u201392. https:\/\/doi.org\/10.1016\/j.cardiores.2004.09.024","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10220_CR19","doi-asserted-by":"publisher","first-page":"H738","DOI":"10.1152\/ajpheart.2001.280.2.H738","volume":"280","author":"K Kusumoto","year":"2001","unstructured":"Kusumoto K, Haist JV, Karmazyn M (2001) Na(+)\/H(+) exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 280(2):H738-745. https:\/\/doi.org\/10.1152\/ajpheart.2001.280.2.H738","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10220_CR20","doi-asserted-by":"crossref","unstructured":"Mraiche F, Oka T, Gan XT, Karmazyn M, Fliegel L (2011) Activated NHE1 is required to induce early cardiac hypertrophy in mice. Basic Res in Cardiol 106(4):603\u2013616","DOI":"10.1007\/s00395-011-0161-4"},{"issue":"1","key":"10220_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1172\/JCI62834","volume":"123","author":"AR Marks","year":"2013","unstructured":"Marks AR (2013) Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest 123(1):46\u201352. https:\/\/doi.org\/10.1172\/JCI62834","journal-title":"J Clin Invest"},{"issue":"6","key":"10220_CR22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1161\/CIRCRESAHA.113.301651","volume":"113","author":"M Luo","year":"2013","unstructured":"Luo M, Anderson ME (2013) Mechanisms of altered Ca(2)(+) handling in heart failure. Circ Res 113(6):690\u2013708. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.301651","journal-title":"Circ Res"},{"issue":"36","key":"10220_CR23","doi-asserted-by":"publisher","first-page":"11389","DOI":"10.1073\/pnas.1513047112","volume":"112","author":"G Santulli","year":"2015","unstructured":"Santulli G, Xie W, Reiken SR, Marks AR (2015) Mitochondrial calcium overload is a key determinant in heart failure. Proc Natl Acad Sci USA 112(36):11389\u201311394. https:\/\/doi.org\/10.1073\/pnas.1513047112","journal-title":"Proc Natl Acad Sci USA"},{"key":"10220_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.636295","volume":"9","author":"KL Lin","year":"2021","unstructured":"Lin KL, Chen SD, Lin KJ, Liou CW, Chuang YC, Wang PW, Chuang JH, Lin TK (2021) Quality matters? The involvement of mitochondrial quality control in cardiovascular disease. Front Cell Dev Biol 9:636295. https:\/\/doi.org\/10.3389\/fcell.2021.636295","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"10220_CR25","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1172\/JCI120849","volume":"128","author":"B Zhou","year":"2018","unstructured":"Zhou B, Tian R (2018) Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest 128(9):3716\u20133726. https:\/\/doi.org\/10.1172\/JCI120849","journal-title":"J Clin Invest"},{"issue":"12","key":"10220_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0355-7","volume":"51","author":"JN Peoples","year":"2019","unstructured":"Peoples JN, Saraf A, Ghazal N, Pham TT, Kwong JQ (2019) Mitochondrial dysfunction and oxidative stress in heart disease. Exp Mol Med 51(12):1\u201313. https:\/\/doi.org\/10.1038\/s12276-019-0355-7","journal-title":"Exp Mol Med"},{"issue":"1","key":"10220_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jacbts.2019.07.009","volume":"5","author":"HN Sabbah","year":"2020","unstructured":"Sabbah HN (2020) Targeting the mitochondria in heart failure: a translational perspective. JACC Basic Transl Sci 5(1):88\u2013106. https:\/\/doi.org\/10.1016\/j.jacbts.2019.07.009","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"10220_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/01.fjc.0000432861.55968.a6","volume":"63","author":"AA Knowlton","year":"2014","unstructured":"Knowlton AA, Chen L, Malik ZA (2014) Heart failure and mitochondrial dysfunction: the role of mitochondrial fission\/fusion abnormalities and new therapeutic strategies. J Cardiovasc Pharmacol 63(3):196\u2013206. https:\/\/doi.org\/10.1097\/01.fjc.0000432861.55968.a6","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"10220_CR29","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.cjca.2016.12.013","volume":"33","author":"GD Lopaschuk","year":"2017","unstructured":"Lopaschuk GD (2017) Metabolic modulators in heart disease: past, present, and future. Can J Cardiol 33(7):838\u2013849. https:\/\/doi.org\/10.1016\/j.cjca.2016.12.013","journal-title":"Can J Cardiol"},{"issue":"8","key":"10220_CR30","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/bph.12475","volume":"171","author":"N Fillmore","year":"2014","unstructured":"Fillmore N, Mori J, Lopaschuk GD (2014) Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol 171(8):2080\u20132090. https:\/\/doi.org\/10.1111\/bph.12475","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10220_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/s0008-6363(96)00245-3","volume":"33","author":"WC Stanley","year":"1997","unstructured":"Stanley WC, Lopaschuk GD, Hall JL, McCormack JG (1997) Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions Cardiovasc Res 33(2):243\u2013257. https:\/\/doi.org\/10.1016\/s0008-6363(96)00245-3","journal-title":"Potential for pharmacological interventions Cardiovasc Res"},{"issue":"4","key":"10220_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/cvr\/cvx017","volume":"113","author":"J Ritterhoff","year":"2017","unstructured":"Ritterhoff J, Tian R (2017) Metabolism in cardiomyopathy: every substrate matters. Cardiovasc Res 113(4):411\u2013421. https:\/\/doi.org\/10.1093\/cvr\/cvx017","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10220_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jacbts.2016.11.009","volume":"2","author":"AR Wende","year":"2017","unstructured":"Wende AR, Brahma MK, McGinnis GR, Young ME (2017) Metabolic origins of heart failure. JACC Basic Transl Sci 2(3):297\u2013310. https:\/\/doi.org\/10.1016\/j.jacbts.2016.11.009","journal-title":"JACC Basic Transl Sci"},{"key":"10220_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2020.158813","volume":"12","author":"GD Lopaschuk","year":"1865","unstructured":"Lopaschuk GD, Karwi QG, Ho KL, Pherwani S (1865) Ketema EB (2020) Ketone metabolism in the failing heart. Biochim Biophys Acta Mol Cell Biol Lipids 12:158813. https:\/\/doi.org\/10.1016\/j.bbalip.2020.158813","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"22","key":"10220_CR35","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1161\/CIRCULATIONAHA.119.045033","volume":"141","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj S, Kelly DP, Margulies KB (2020) Implications of altered ketone metabolism and therapeutic ketosis in heart failure. Circulation 141(22):1800\u20131812. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.045033","journal-title":"Circulation"},{"issue":"5","key":"10220_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","volume":"17","author":"L Adamo","year":"2020","unstructured":"Adamo L, Rocha-Resende C, Prabhu SD, Mann DL (2020) Reappraising the role of inflammation in heart failure. Nat Rev Cardiol 17(5):269\u2013285. https:\/\/doi.org\/10.1038\/s41569-019-0315-x","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10220_CR37","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","volume":"75","author":"SP Murphy","year":"2020","unstructured":"Murphy SP, Kakkar R, McCarthy CP, Januzzi JL Jr (2020) Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol 75(11):1324\u20131340. https:\/\/doi.org\/10.1016\/j.jacc.2020.01.014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10220_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263\u2013271. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10220_CR39","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","volume":"119","author":"SA Dick","year":"2016","unstructured":"Dick SA, Epelman S (2016) Chronic heart failure and inflammation: what do we really know? Circ Res 119(1):159\u2013176. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308030","journal-title":"Circ Res"},{"issue":"1","key":"10220_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","volume":"134","author":"SJ Shah","year":"2016","unstructured":"Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ (2016) Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 134(1):73\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021884","journal-title":"Circulation"},{"key":"10220_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.freeradbiomed.2020.02.026","volume":"157","author":"A Daiber","year":"2020","unstructured":"Daiber A, Chlopicki S (2020) Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: evidence for redox-based therapies. Free Radic Biol Med 157:15\u201337. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.02.026","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"10220_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00395-018-0679-9","volume":"113","author":"M Park","year":"2018","unstructured":"Park M, Sandner P, Krieg T (2018) cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. Basic Res Cardiol 113(4):24. https:\/\/doi.org\/10.1007\/s00395-018-0679-9","journal-title":"Basic Res Cardiol"},{"issue":"5","key":"10220_CR43","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1177\/2047487319870344","volume":"27","author":"A Aimo","year":"2020","unstructured":"Aimo A, Castiglione V, Borrelli C, Saccaro LF, Franzini M, Masi S, Emdin M, Giannoni A (2020) Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies. Eur J Prev Cardiol 27(5):494\u2013510. https:\/\/doi.org\/10.1177\/2047487319870344","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10220_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jacc.2017.05.035","volume":"70","author":"T Munzel","year":"2017","unstructured":"Munzel T, Camici GG, Maack C, Bonetti NR, Fuster V, Kovacic JC (2017) Impact of oxidative stress on the heart and vasculature: part 2 of a 3-part series. J Am Coll Cardiol 70(2):212\u2013229. https:\/\/doi.org\/10.1016\/j.jacc.2017.05.035","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10220_CR45","doi-asserted-by":"publisher","first-page":"H2181","DOI":"10.1152\/ajpheart.00554.2011","volume":"301","author":"H Tsutsui","year":"2011","unstructured":"Tsutsui H, Kinugawa S, Matsushima S (2011) Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 301(6):H2181-2190. https:\/\/doi.org\/10.1152\/ajpheart.00554.2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"10220_CR46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ejhf.1320","volume":"21","author":"A van der Pol","year":"2019","unstructured":"van der Pol A, van Gilst WH, Voors AA, van der Meer P (2019) Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail 21(4):425\u2013435. https:\/\/doi.org\/10.1002\/ejhf.1320","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10220_CR47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.yjmcc.2008.01.005","volume":"44","author":"M Karmazyn","year":"2008","unstructured":"Karmazyn M, Kilic A, Javadov S (2008) The role of NHE-1 in myocardial hypertrophy and remodelling. J Mol Cell Cardiol 44(4):647\u2013653. https:\/\/doi.org\/10.1016\/j.yjmcc.2008.01.005","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"10220_CR48","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0008-6363(96)88573-7","volume":"29","author":"H Matsui","year":"1995","unstructured":"Matsui H, Barry WH, Livsey C, Spitzer KW (1995) Angiotensin II stimulates sodium-hydrogen exchange in adult rabbit ventricular myocytes. Cardiovasc Res 29(2):215\u2013221","journal-title":"Cardiovasc Res"},{"issue":"3 Pt 2","key":"10220_CR49","doi-asserted-by":"publisher","first-page":"H1131","DOI":"10.1152\/ajpheart.1997.272.3.H1131","volume":"272","author":"A Mattiazzi","year":"1997","unstructured":"Mattiazzi A, Perez NG, Vila-Petroff MG, Alvarez B, Camilion de Hurtado MC, Cingolani HE (1997) Dissociation between positive inotropic and alkalinizing effects of angiotensin II in feline myocardium. Am J Physiol 272(3 Pt 2):H1131-1136. https:\/\/doi.org\/10.1152\/ajpheart.1997.272.3.H1131","journal-title":"Am J Physiol"},{"issue":"6","key":"10220_CR50","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00424-002-0990-y","volume":"445","author":"XH Xiao","year":"2003","unstructured":"Xiao XH, Allen DG (2003) The role of endogenous angiotensin II in ischaemia, reperfusion and preconditioning of the isolated rat heart. Pflugers Arch 445(6):643\u2013650. https:\/\/doi.org\/10.1007\/s00424-002-0990-y","journal-title":"Pflugers Arch"},{"issue":"1","key":"10220_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/hr.2013.108","volume":"37","author":"G Liu","year":"2014","unstructured":"Liu G, Hitomi H, Rahman A, Nakano D, Mori H, Masaki T, Ma H, Iwamoto T, Kobori H, Nishiyama A (2014) High sodium augments angiotensin II-induced vascular smooth muscle cell proliferation through the ERK 1\/2-dependent pathway. Hypertens Res 37(1):13\u201318. https:\/\/doi.org\/10.1038\/hr.2013.108","journal-title":"Hypertens Res"},{"issue":"5 Pt 1","key":"10220_CR52","doi-asserted-by":"publisher","first-page":"C1096","DOI":"10.1152\/ajpcell.1992.263.5.C1096","volume":"263","author":"MA Wallert","year":"1992","unstructured":"Wallert MA, Frohlich O (1992) Alpha 1-adrenergic stimulation of Na-H exchange in cardiac myocytes. Am J Physiol 263(5 Pt 1):C1096-1102. https:\/\/doi.org\/10.1152\/ajpcell.1992.263.5.C1096","journal-title":"Am J Physiol"},{"issue":"7","key":"10220_CR53","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1161\/01.res.0000014966.97486.c0","volume":"90","author":"S Engelhardt","year":"2002","unstructured":"Engelhardt S, Hein L, Keller U, Klambt K, Lohse MJ (2002) Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ Res 90(7):814\u2013819. https:\/\/doi.org\/10.1161\/01.res.0000014966.97486.c0","journal-title":"Circ Res"},{"issue":"10","key":"10220_CR54","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1161\/01.res.82.10.1078","volume":"82","author":"H Yokoyama","year":"1998","unstructured":"Yokoyama H, Yasutake M, Avkiran M (1998) Alpha1-adrenergic stimulation of sarcolemmal Na+-H+ exchanger activity in rat ventricular myocytes: evidence for selective mediation by the alpha1A-adrenoceptor subtype. Circ Res 82(10):1078\u20131085. https:\/\/doi.org\/10.1161\/01.res.82.10.1078","journal-title":"Circ Res"},{"key":"10220_CR55","doi-asserted-by":"crossref","unstructured":"Boedtkjer E, Damkier HH, Aalkjaer C (2012) NHE1 knockout reduces blood pressure and arterial media\/lumen ratio with no effect on resting pH(i) in the vascular wall. J Physiol 590(8):1895\u20131906","DOI":"10.1113\/jphysiol.2011.227132"},{"issue":"2","key":"10220_CR56","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1161\/01.res.75.2.369","volume":"75","author":"N Khandoudi","year":"1994","unstructured":"Khandoudi N, Ho J, Karmazyn M (1994) Role of Na(+)-H+ exchange in mediating effects of endothelin-1 on normal and ischemic\/reperfused hearts. Circ Res 75(2):369\u2013378. https:\/\/doi.org\/10.1161\/01.res.75.2.369","journal-title":"Circ Res"},{"key":"10220_CR57","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1113\/jphysiol.1993.sp019917","volume":"471","author":"ML Wu","year":"1993","unstructured":"Wu ML, Tseng YZ (1993) The modulatory effects of endothelin-1, carbachol and isoprenaline upon Na(+)-H+ exchange in dog cardiac Purkinje fibres. J Physiol 471:583\u2013597. https:\/\/doi.org\/10.1113\/jphysiol.1993.sp019917","journal-title":"J Physiol"},{"issue":"5","key":"10220_CR58","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.yjmcc.2006.05.016","volume":"41","author":"RA Dulce","year":"2006","unstructured":"Dulce RA, Hurtado C, Ennis IL, Garciarena CD, Alvarez MC, Caldiz C, Pierce GN, Portiansky EL, Chiappe de Cingolani GE, Camilion de Hurtado MC (2006) Endothelin-1 induced hypertrophic effect in neonatal rat cardiomyocytes: involvement of Na+\/H+ and Na+\/Ca2+ exchangers. J Mol Cell Cardiol 41(5):807\u2013815. https:\/\/doi.org\/10.1016\/j.yjmcc.2006.05.016","journal-title":"J Mol Cell Cardiol"},{"issue":"16","key":"10220_CR59","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1128\/MCB.00145-12","volume":"32","author":"T Hisamitsu","year":"2012","unstructured":"Hisamitsu T, Nakamura TY, Wakabayashi S (2012) Na(+)\/H(+) exchanger 1 directly binds to calcineurin A and activates downstream NFAT signaling, leading to cardiomyocyte hypertrophy. Mol Cell Biol 32(16):3265\u20133280. https:\/\/doi.org\/10.1128\/MCB.00145-12","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10220_CR60","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00125-007-0628-x","volume":"50","author":"A Darmellah","year":"2007","unstructured":"Darmellah A, Baetz D, Prunier F, Tamareille S, Rucker-Martin C, Feuvray D (2007) Enhanced activity of the myocardial Na+\/H+ exchanger contributes to left ventricular hypertrophy in the Goto-Kakizaki rat model of type 2 diabetes: critical role of Akt. Diabetologia 50(6):1335\u20131344. https:\/\/doi.org\/10.1007\/s00125-007-0628-x","journal-title":"Diabetologia"},{"issue":"6","key":"10220_CR61","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1073\/pnas.89.6.2424","volume":"89","author":"S Wakabayashi","year":"1992","unstructured":"Wakabayashi S, Fafournoux P, Sardet C, Pouyssegur J (1992) The Na+\/H+ antiporter cytoplasmic domain mediates growth factor signals and controls \u201cH(+)-sensing.\u201d Proc Natl Acad Sci USA 89(6):2424\u20132428. https:\/\/doi.org\/10.1073\/pnas.89.6.2424","journal-title":"Proc Natl Acad Sci USA"},{"key":"10220_CR62","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.yjmcc.2013.02.007","volume":"61","author":"S Wakabayashi","year":"2013","unstructured":"Wakabayashi S, Hisamitsu T, Nakamura TY (2013) Regulation of the cardiac Na(+)\/H(+) exchanger in health and disease. J Mol Cell Cardiol 61:68\u201376. https:\/\/doi.org\/10.1016\/j.yjmcc.2013.02.007","journal-title":"J Mol Cell Cardiol"},{"issue":"5","key":"10220_CR63","doi-asserted-by":"publisher","first-page":"H2237","DOI":"10.1152\/ajpheart.00855.2006","volume":"292","author":"K Imahashi","year":"2007","unstructured":"Imahashi K, Mraiche F, Steenbergen C, Murphy E, Fliegel L (2007) Overexpression of the Na+\/H+ exchanger and ischemia-reperfusion injury in the myocardium. Am J Physiol Heart Circ Physiol 292(5):H2237-2247. https:\/\/doi.org\/10.1152\/ajpheart.00855.2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1\u20132","key":"10220_CR64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11010-009-0337-5","volume":"338","author":"P Karki","year":"2010","unstructured":"Karki P, Fliegel L (2010) Overexpression of the NHE1 isoform of the Na(+)\/H (+) exchanger causes elevated apoptosis in isolated cardiomyocytes after hypoxia\/reoxygenation challenge. Mol Cell Biochem 338(1\u20132):47\u201357. https:\/\/doi.org\/10.1007\/s11010-009-0337-5","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"10220_CR65","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1161\/01.HYP.0000056769.73726.E5","volume":"41","author":"G Fujisawa","year":"2003","unstructured":"Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S (2003) Na\/H exchange isoform 1 is involved in mineralocorticoid\/salt-induced cardiac injury. Hypertension 41(3):493\u2013498. https:\/\/doi.org\/10.1161\/01.HYP.0000056769.73726.E5","journal-title":"Hypertension"},{"issue":"9","key":"10220_CR66","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1161\/01.res.85.9.777","volume":"85","author":"M Karmazyn","year":"1999","unstructured":"Karmazyn M, Gan XT, Humphreys RA, Yoshida H, Kusumoto K (1999) The myocardial Na(+)-H(+) exchange: structure, regulation, and its role in heart disease. Circ Res 85(9):777\u2013786. https:\/\/doi.org\/10.1161\/01.res.85.9.777","journal-title":"Circ Res"},{"issue":"8","key":"10220_CR67","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/01.RES.0000094746.24774.DC","volume":"93","author":"Y Wang","year":"2003","unstructured":"Wang Y, Meyer JW, Ashraf M, Shull GE (2003) Mice with a null mutation in the NHE1 Na+-H+ exchanger are resistant to cardiac ischemia-reperfusion injury. Circ Res 93(8):776\u2013782. https:\/\/doi.org\/10.1161\/01.RES.0000094746.24774.DC","journal-title":"Circ Res"},{"issue":"1","key":"10220_CR68","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1067\/mtc.2003.65","volume":"125","author":"S Muraki","year":"2003","unstructured":"Muraki S, Morris CD, Budde JM, Zhao ZQ, Guyton RA, Vinten-Johansen J (2003) Blood cardioplegia supplementation with the sodium-hydrogen ion exchange inhibitor cariporide to attenuate infarct size and coronary artery endothelial dysfunction after severe regional ischemia in a canine model. J Thorac Cardiovasc Surg 125(1):155\u2013164. https:\/\/doi.org\/10.1067\/mtc.2003.65","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"10220_CR69","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/sj.bjp.0702566","volume":"127","author":"NN Aye","year":"1999","unstructured":"Aye NN, Komori S, Hashimoto K (1999) Effects and interaction, of cariporide and preconditioning on cardiac arrhythmias and infarction in rat in vivo. Br J Pharmacol 127(4):1048\u20131055. https:\/\/doi.org\/10.1038\/sj.bjp.0702566","journal-title":"Br J Pharmacol"},{"issue":"1\u20132","key":"10220_CR70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/a:1024985931797","volume":"250","author":"M ten Hove","year":"2003","unstructured":"ten Hove M, van Emous JG, van Echteld CJ (2003) Na+ overload during ischemia and reperfusion in rat hearts: comparison of the Na+\/H+ exchange blockers EIPA, cariporide and eniporide. Mol Cell Biochem 250(1\u20132):47\u201354. https:\/\/doi.org\/10.1023\/a:1024985931797","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"10220_CR71","first-page":"175","volume":"286","author":"RJ Gumina","year":"1998","unstructured":"Gumina RJ, Mizumura T, Beier N, Schelling P, Schultz JJ, Gross GJ (1998) A new sodium\/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion. J Pharmacol Exp Ther 286(1):175\u2013183","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10220_CR72","first-page":"254","volume":"297","author":"DR Knight","year":"2001","unstructured":"Knight DR, Smith AH, Flynn DM, MacAndrew JT, Ellery SS, Kong JX, Marala RB, Wester RT, Guzman-Perez A, Hill RJ, Magee WP, Tracey WR (2001) A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo. J Pharmacol Exp Ther 297(1):254\u2013259","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10220_CR73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1527-3466.2003.tb00103.x","volume":"21","author":"WR Tracey","year":"2003","unstructured":"Tracey WR, Allen MC, Frazier DE, Fossa AA, Johnson CG, Marala RB, Knight DR, Guzman-Perez A (2003) Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev 21(1):17\u201332. https:\/\/doi.org\/10.1111\/j.1527-3466.2003.tb00103.x","journal-title":"Cardiovasc Drug Rev"},{"key":"10220_CR74","doi-asserted-by":"crossref","unstructured":"Clements-Jewery H, Sutherland FJ, Allen MC, Tracey WR, Avkiran M (2004) Cardioprotective efficacy of zoniporide, a potent and selective inhibitor of Na+\/H+ exchanger isoform 1, in an experimental model of cardiopulmonary bypass. Br J Pharmacol 142(1):57\u201366","DOI":"10.1038\/sj.bjp.0705749"},{"key":"10220_CR75","doi-asserted-by":"publisher","unstructured":"Theroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS, Tognoni G, White HD, Willerson JT, Jessel A (2000) Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation 102(25):3032\u20133038. https:\/\/doi.org\/10.1161\/01.cir.102.25.3032","DOI":"10.1161\/01.cir.102.25.3032"},{"issue":"2","key":"10220_CR76","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/s0022-5223(03)00209-5","volume":"126","author":"SW Boyce","year":"2003","unstructured":"Boyce SW, Bartels C, Bolli R, Chaitman B, Chen JC, Chi E, Jessel A, Kereiakes D, Knight J, Thulin L, Theroux P, Investigators GDIANS (2003) Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg 126(2):420\u2013427. https:\/\/doi.org\/10.1016\/s0022-5223(03)00209-5","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10220_CR77","doi-asserted-by":"publisher","unstructured":"Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, Linssen G, Tebbe U, Schroder R, Tiemann R, Machnig T, Neuhaus KL, Investigators E (2001) The Na(+)\/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 38(6):1644\u20131650. https:\/\/doi.org\/10.1016\/s0735-1097(01)01608-4","DOI":"10.1016\/s0735-1097(01)01608-4"},{"issue":"2","key":"10220_CR78","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1527-3466.2007.00010.x","volume":"25","author":"K Leineweber","year":"2007","unstructured":"Leineweber K, Heusch G, Schulz R (2007) Regulation and role of the presynaptic and myocardial Na+\/H+ exchanger NHE1: effects on the sympathetic nervous system in heart failure. Cardiovasc Drug Rev 25(2):123\u2013131. https:\/\/doi.org\/10.1111\/j.1527-3466.2007.00010.x","journal-title":"Cardiovasc Drug Rev"},{"issue":"8","key":"10220_CR79","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1161\/CIRCRESAHA.108.175141","volume":"103","author":"TY Nakamura","year":"2008","unstructured":"Nakamura TY, Iwata Y, Arai Y, Komamura K, Wakabayashi S (2008) Activation of Na+\/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ Res 103(8):891\u2013899. https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.175141","journal-title":"Circ Res"},{"issue":"5","key":"10220_CR80","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1253\/jcj.54.535","volume":"54","author":"M Hori","year":"1990","unstructured":"Hori M, Nakatsubo N, Kagiya T, Iwai K, Sato H, Iwakura K, Kitabatake A, Kamada T (1990) The role of Na+\/H+ exchange in norepinephrine-induced protein synthesis in neonatal cultured rat cardiomyocytes. Jpn Circ J 54(5):535\u2013539. https:\/\/doi.org\/10.1253\/jcj.54.535","journal-title":"Jpn Circ J"},{"issue":"4","key":"10220_CR81","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1006\/jmcc.1998.0640","volume":"30","author":"KD Schluter","year":"1998","unstructured":"Schluter KD, Schafer M, Balser C, Taimor G, Piper HM (1998) Influence of pHi and creatine phosphate on alpha-adrenoceptor-mediated cardiac hypertrophy. J Mol Cell Cardiol 30(4):763\u2013771. https:\/\/doi.org\/10.1006\/jmcc.1998.0640","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"10220_CR82","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1161\/01.HYP.0000071180.12012.6E","volume":"41","author":"IL Ennis","year":"2003","unstructured":"Ennis IL, Escudero EM, Console GM, Camihort G, Dumm CG, Seidler RW, Camilion de Hurtado MC, Cingolani HE (2003) Regression of isoproterenol-induced cardiac hypertrophy by Na+\/H+ exchanger inhibition. Hypertension 41(6):1324\u20131329. https:\/\/doi.org\/10.1161\/01.HYP.0000071180.12012.6E","journal-title":"Hypertension"},{"issue":"4","key":"10220_CR83","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/s0008-6363(02)00809-x","volume":"57","author":"A Baartscheer","year":"2003","unstructured":"Baartscheer A, Schumacher CA, van Borren MM, Belterman CN, Coronel R, Fiolet JW (2003) Increased Na+\/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res 57(4):1015\u20131024. https:\/\/doi.org\/10.1016\/s0008-6363(02)00809-x","journal-title":"Cardiovasc Res"},{"key":"10220_CR84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1475-2840-11-33","volume":"11","author":"R Anzawa","year":"2012","unstructured":"Anzawa R, Seki S, Nagoshi T, Taniguchi I, Feuvray D, Yoshimura M (2012) The role of Na+\/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from type 2 diabetic db\/db mice. Cardiovasc Diabetol 11:33. https:\/\/doi.org\/10.1186\/1475-2840-11-33","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10220_CR85","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bbrc.2012.09.050","volume":"427","author":"YM Sun","year":"2012","unstructured":"Sun YM, Su Y, Li J, Tian Y, Wang LF (2012) Role of the Na(+)\/H(+) exchanger on the development of diabetes mellitus and its chronic complications. Biochem Biophys Res Commun 427(2):229\u2013231. https:\/\/doi.org\/10.1016\/j.bbrc.2012.09.050","journal-title":"Biochem Biophys Res Commun"},{"key":"10220_CR86","doi-asserted-by":"publisher","unstructured":"Williams B, Howard RL (1994) Glucose-induced changes in Na+\/H+ antiport activity and gene expression in cultured vascular smooth muscle cells. Role of protein kinase C. J Clin Invest 93(6):2623\u20132631. https:\/\/doi.org\/10.1172\/JCI117275","DOI":"10.1172\/JCI117275"},{"issue":"3","key":"10220_CR87","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.diabres.2005.03.038","volume":"70","author":"RJ Dilley","year":"2005","unstructured":"Dilley RJ, Farrelly CA, Allen TJ, Jandeleit-Dahm K, Cooper ME, Morahan G, Little PJ (2005) Diabetes induces Na\/H exchange activity and hypertrophy of rat mesenteric but not basilar arteries. Diabetes Res and Clin Pract 70(3):201\u2013208. https:\/\/doi.org\/10.1016\/j.diabres.2005.03.038","journal-title":"Diabetes Res and Clin Pract"},{"issue":"12","key":"10220_CR88","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/01.res.87.12.1133","volume":"87","author":"K Jandeleit-Dahm","year":"2000","unstructured":"Jandeleit-Dahm K, Hannan KM, Farrelly CA, Allen TJ, Rumble JR, Gilbert RE, Cooper ME, Little PJ (2000) Diabetes-induced vascular hypertrophy is accompanied by activation of Na(+)-H(+) exchange and prevented by Na(+)-H(+) exchange inhibition. Circ Res 87(12):1133\u20131140. https:\/\/doi.org\/10.1161\/01.res.87.12.1133","journal-title":"Circ Res"},{"issue":"5","key":"10220_CR89","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/dmrr.322","volume":"18","author":"D Hileeto","year":"2002","unstructured":"Hileeto D, Cukiernik M, Mukherjee S, Evans T, Barbin Y, Downey D, Karmazyn M, Chakrabarti S (2002) Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium. Diabetes Metab Res Rev 18(5):386\u2013394. https:\/\/doi.org\/10.1002\/dmrr.322","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10220_CR90","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","volume":"19","author":"M Arow","year":"2020","unstructured":"Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham NG, Freimark D, Kornowski R, Aravot D, Hochhauser E, Arad M (2020) Sodium-glucose cotransporter 2 inhibitor dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc Diabetol 19(1):7. https:\/\/doi.org\/10.1186\/s12933-019-0980-4","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10220_CR91","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jacbts.2019.07.010","volume":"4","author":"O Iborra-Egea","year":"2019","unstructured":"Iborra-Egea O, Santiago-Vacas E, Yurista SR, Lupon J, Packer M, Heymans S, Zannad F, Butler J, Pascual-Figal D, Lax A, Nunez J, de Boer RA, Bayes-Genis A (2019) Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. JACC Basic Transl Sci 4(7):831\u2013840. https:\/\/doi.org\/10.1016\/j.jacbts.2019.07.010","journal-title":"JACC Basic Transl Sci"},{"key":"10220_CR92","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-020-00809-4","author":"K Jiang","year":"2021","unstructured":"Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian J, Xu S, Xu Y, Hwa J, Li J, Shang H, Xiang Y (2021) Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. https:\/\/doi.org\/10.1007\/s13238-020-00809-4","journal-title":"Protein Cell"},{"issue":"3","key":"10220_CR93","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00424-006-0044-y","volume":"452","author":"SF Pedersen","year":"2006","unstructured":"Pedersen SF (2006) The Na+\/H+ exchanger NHE1 in stress-induced signal transduction: implications for cell proliferation and cell death. Pflugers Arch 452(3):249\u2013259. https:\/\/doi.org\/10.1007\/s00424-006-0044-y","journal-title":"Pflugers Arch"},{"issue":"9","key":"10220_CR94","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1161\/CIRCULATIONAHA.106.626929","volume":"115","author":"HE Cingolani","year":"2007","unstructured":"Cingolani HE, Ennis IL (2007) Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation 115(9):1090\u20131100. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.626929","journal-title":"Circulation"},{"key":"10220_CR95","doi-asserted-by":"crossref","unstructured":"Baumgartner M, Patel H, Barber DL (2004) Na(+)\/H(+) exchanger NHE1 as plasma membrane scaffold in the assembly of signaling complexes. Am J Physiol Cell Physiol 287(4):C844\u2013850","DOI":"10.1152\/ajpcell.00094.2004"},{"issue":"1","key":"10220_CR96","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1038\/s41467-018-07700-1","volume":"9","author":"P Bisignano","year":"2018","unstructured":"Bisignano P, Ghezzi C, Jo H, Polizzi NF, Althoff T, Kalyanaraman C, Friemann R, Jacobson MP, Wright EM, Grabe M (2018) Inhibitor binding mode and allosteric regulation of Na(+)-glucose symporters. Nat Commun 9(1):5245. https:\/\/doi.org\/10.1038\/s41467-018-07700-1","journal-title":"Nat Commun"},{"issue":"9","key":"10220_CR97","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00424-020-02448-4","volume":"472","author":"EM Wright","year":"2020","unstructured":"Wright EM (2020) SGLT2 and cancer. Pflugers Arch 472(9):1407\u20131414. https:\/\/doi.org\/10.1007\/s00424-020-02448-4","journal-title":"Pflugers Arch"},{"key":"10220_CR98","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa323","author":"YJ Chung","year":"2020","unstructured":"Chung YJ, Park KC, Tokar S, Eykyn TR, Fuller W, Pavlovic D, Swietach P, Shattock MJ (2020) Off-target effects of SGLT2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res. https:\/\/doi.org\/10.1093\/cvr\/cvaa323","journal-title":"Cardiovasc Res"},{"key":"10220_CR99","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab129","author":"CJ Zuurbier","year":"2021","unstructured":"Zuurbier CJ, Baartscheer A, Schumacher CA, Fiolet JWT, Coronel R (2021) SGLT2 inhibitor empagliflozin inhibits the cardiac Na+\/H+ exchanger 1: persistent inhibition under various experimental conditions. Cardiovasc Res. https:\/\/doi.org\/10.1093\/cvr\/cvab129","journal-title":"Cardiovasc Res"},{"key":"10220_CR100","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab184","author":"YJ Chung","year":"2021","unstructured":"Chung YJ, Park KC, Tokar S, Eykyn TR, Fuller W, Pavlovic D, Swietach P, Shattock MJ (2021) SGLT2 inhibitors and the cardiac Na+\/H+ exchanger-1: the plot thickens. Cardiovasc Res. https:\/\/doi.org\/10.1093\/cvr\/cvab184","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10220_CR101","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1152\/physiolgenomics.00064.2010","volume":"42","author":"J Xue","year":"2010","unstructured":"Xue J, Mraiche F, Zhou D, Karmazyn M, Oka T, Fliegel L, Haddad GG (2010) Elevated myocardial Na+\/H+ exchanger isoform 1 activity elicits gene expression that leads to cardiac hypertrophy. Physiol Genomics 42(3):374\u2013383. https:\/\/doi.org\/10.1152\/physiolgenomics.00064.2010","journal-title":"Physiol Genomics"},{"key":"10220_CR102","doi-asserted-by":"publisher","unstructured":"Salameh A, Dhein S, Beuckelmann DJ (2002) Role of the cardiac Na(+)\/H(+)exchanger in [Ca(2+)](i)and [Na(+)](i)handling during intracellular acidosis. Effect of cariporide (Hoe 642). Pharmacol Res 45(1):35\u201341. https:\/\/doi.org\/10.1006\/phrs.2001.0908","DOI":"10.1006\/phrs.2001.0908"},{"key":"10220_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13024","author":"M Trum","year":"2020","unstructured":"Trum M, Riechel J, Lebek S, Pabel S, Sossalla ST, Hirt S, Arzt M, Maier LS, Wagner S (2020) Empagliflozin inhibits Na(+) \/H(+) exchanger activity in human atrial cardiomyocytes. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.13024","journal-title":"ESC Heart Fail"},{"issue":"10","key":"10220_CR104","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/cvr\/cvz004","volume":"115","author":"L Uthman","year":"2019","unstructured":"Uthman L, Nederlof R, Eerbeek O, Baartscheer A, Schumacher C, Buchholtz N, Hollmann MW, Coronel R, Weber NC, Zuurbier CJ (2019) Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts. Cardiovasc Res 115(10):1533\u20131545. https:\/\/doi.org\/10.1093\/cvr\/cvz004","journal-title":"Cardiovasc Res"},{"key":"10220_CR105","doi-asserted-by":"publisher","unstructured":"Ventura-Clapier R, Veksler V (1994) Myocardial ischemic contracture. Metabolites affect rigor tension development and stiffness. Circ Res 74(5):920\u2013929. https:\/\/doi.org\/10.1161\/01.res.74.5.920","DOI":"10.1161\/01.res.74.5.920"},{"key":"10220_CR106","doi-asserted-by":"publisher","unstructured":"Pedersen SF, King SA, Nygaard EB, Rigor RR, Cala PM (2007) NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity. J Biol Chem 282(27):19716\u201319727. https:\/\/doi.org\/10.1074\/jbc.M701637200","DOI":"10.1074\/jbc.M701637200"},{"key":"10220_CR107","doi-asserted-by":"publisher","unstructured":"Garciarena CD, Fantinelli JC, Caldiz CI, Chiappe de Cingolani G, Ennis IL, Perez NG, Cingolani HE, Mosca SM (2011) Myocardial reperfusion injury: reactive oxygen species vs. NHE-1 reactivation. Cell Physiol Biochem 27(1):13\u201322. https:\/\/doi.org\/10.1159\/000325201","DOI":"10.1159\/000325201"},{"key":"10220_CR108","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ijms22115437","volume":"22","author":"J Goerg","year":"2021","unstructured":"Goerg J, Sommerfeld M, Greiner B, Lauer D, Seckin Y, Kulikov A, Ivkin D, Kintscher U, Okovityi S, Kaschina E (2021) Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a. Int J Mol Sci 22:11. https:\/\/doi.org\/10.3390\/ijms22115437","journal-title":"Int J Mol Sci"},{"key":"10220_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.592233","volume":"7","author":"H Zhang","year":"2020","unstructured":"Zhang H, Uthman L, Bakker D, Sari S, Chen S, Hollmann MW, Coronel R, Weber NC, Houten SM, van Weeghel M, Zuurbier CJ (2020) Empagliflozin decreases lactate generation in an NHE-1 dependent fashion and increases alpha-ketoglutarate synthesis from palmitate in type II diabetic mouse hearts. Front Cardiovasc Med 7:592233. https:\/\/doi.org\/10.3389\/fcvm.2020.592233","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10220_CR110","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1161\/CIRCRESAHA.112.265660","volume":"111","author":"AM Walters","year":"2012","unstructured":"Walters AM, Porter GA Jr, Brookes PS (2012) Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res 111(9):1222\u20131236. https:\/\/doi.org\/10.1161\/CIRCRESAHA.112.265660","journal-title":"Circ Res"},{"issue":"9","key":"10220_CR111","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/ni.3796","volume":"18","author":"PS Liu","year":"2017","unstructured":"Liu PS, Wang H, Li X, Chao T, Teav T, Christen S, Di Conza G, Cheng WC, Chou CH, Vavakova M, Muret C, Debackere K, Mazzone M, Huang HD, Fendt SM, Ivanisevic J, Ho PC (2017) alpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol 18(9):985\u2013994. https:\/\/doi.org\/10.1038\/ni.3796","journal-title":"Nat Immunol"},{"issue":"6","key":"10220_CR112","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018298","volume":"10","author":"X Li","year":"2021","unstructured":"Li X, Lu Q, Qiu Y, do Carmo JM, Wang Z, da Silva AA, Mouton A, Omoto ACM, Hall ME, Li J, Hall JE, (2021) Direct cardiac actions of the sodium glucose co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure. J Am Heart Assoc 10(6):e018298. https:\/\/doi.org\/10.1161\/JAHA.120.018298","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10220_CR113","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.yjmcc.2008.12.023","volume":"46","author":"S Javadov","year":"2009","unstructured":"Javadov S, Rajapurohitam V, Kilic A, Zeidan A, Choi A, Karmazyn M (2009) Anti-hypertrophic effect of NHE-1 inhibition involves GSK-3beta-dependent attenuation of mitochondrial dysfunction. J Mol Cell Cardiol 46(6):998\u20131007. https:\/\/doi.org\/10.1016\/j.yjmcc.2008.12.023","journal-title":"J Mol Cell Cardiol"},{"key":"10220_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104781","volume":"157","author":"D Cappetta","year":"2020","unstructured":"Cappetta D, De Angelis A, Ciuffreda LP, Coppini R, Cozzolino A, Micciche A, Dell\u2019Aversana C, D\u2019Amario D, Cianflone E, Scavone C, Santini L, Palandri C, Naviglio S, Crea F, Rota M, Altucci L, Rossi F, Capuano A, Urbanek K, Berrino L (2020) Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. Pharmacol Res 157:104781. https:\/\/doi.org\/10.1016\/j.phrs.2020.104781","journal-title":"Pharmacol Res"},{"issue":"1","key":"10220_CR115","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2337\/db20-0840","volume":"70","author":"JY Shih","year":"2021","unstructured":"Shih JY, Lin YW, Fisch S, Cheng JT, Kang NW, Hong CS, Chen ZC, Chang WT (2021) Dapagliflozin suppresses ER stress and improves subclinical myocardial function in diabetes: from bedside to bench. Diabetes 70(1):262\u2013267. https:\/\/doi.org\/10.2337\/db20-0840","journal-title":"Diabetes"},{"issue":"6","key":"10220_CR116","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","volume":"32","author":"Y Ye","year":"2018","unstructured":"Ye Y, Jia X, Bajaj M, Birnbaum Y (2018) Dapagliflozin attenuates Na(+)\/H(+) exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther 32(6):553\u2013558. https:\/\/doi.org\/10.1007\/s10557-018-6837-3","journal-title":"Cardiovasc Drugs Ther"},{"key":"10220_CR117","doi-asserted-by":"publisher","unstructured":"Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y (2017) SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther 31(2):119\u2013132. https:\/\/doi.org\/10.1007\/s10557-017-6725-2","DOI":"10.1007\/s10557-017-6725-2"},{"key":"10220_CR118","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/ijms20071680","volume":"20","author":"TI Lee","year":"2019","unstructured":"Lee TI, Chen YC, Lin YK, Chung CC, Lu YY, Kao YH, Chen YJ (2019) Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in streptozotocin-induced diabetic rats. Int J Mol Sci 20:7. https:\/\/doi.org\/10.3390\/ijms20071680","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10220_CR119","doi-asserted-by":"publisher","first-page":"12025","DOI":"10.1038\/s41598-021-91546-z","volume":"11","author":"A Bayes-Genis","year":"2021","unstructured":"Bayes-Genis A, Iborra-Egea O, Spitaleri G, Domingo M, Revuelta-Lopez E, Codina P, Cediel G, Santiago-Vacas E, Cserkoova A, Pascual-Figal D, Nunez J, Lupon J (2021) Decoding empagliflozin\u2019s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. Sci Rep 11(1):12025. https:\/\/doi.org\/10.1038\/s41598-021-91546-z","journal-title":"Sci Rep"},{"issue":"8","key":"10220_CR120","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/s0735-1097(01)01287-6","volume":"37","author":"S Sandmann","year":"2001","unstructured":"Sandmann S, Yu M, Kaschina E, Blume A, Bouzinova E, Aalkjaer C, Unger T (2001) Differential effects of angiotensin AT1 and AT2 receptors on the expression, translation and function of the Na+-H+ exchanger and Na+-HCO3- symporter in the rat heart after myocardial infarction. J Am Coll Cardiol 37(8):2154\u20132165. https:\/\/doi.org\/10.1016\/s0735-1097(01)01287-6","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10220_CR121","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00424-011-1020-8","volume":"462","author":"OH Cingolani","year":"2011","unstructured":"Cingolani OH, Perez NG, Ennis IL, Alvarez MC, Mosca SM, Schinella GR, Escudero EM, Console G, Cingolani HE (2011) In vivo key role of reactive oxygen species and NHE-1 activation in determining excessive cardiac hypertrophy. Pflugers Arch 462(5):733\u2013743. https:\/\/doi.org\/10.1007\/s00424-011-1020-8","journal-title":"Pflugers Arch"},{"key":"10220_CR122","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/ijms20081940","volume":"20","author":"JI Beraldo","year":"2019","unstructured":"Beraldo JI, Benetti A, Borges-Junior FA, Arruda-Junior DF, Martins FL, Jensen L, Dariolli R, Shimizu MH, Seguro AC, Luchi WM, Girardi ACC (2019) Cardioprotection conferred by sitagliptin is associated with reduced cardiac angiotensin II\/angiotensin-(1\u20137) balance in experimental chronic kidney disease. Int J Mol Sci 20:8. https:\/\/doi.org\/10.3390\/ijms20081940","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10220_CR123","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s00394-017-1482-3","volume":"57","author":"W Tunapong","year":"2018","unstructured":"Tunapong W, Apaijai N, Yasom S, Tanajak P, Wanchai K, Chunchai T, Kerdphoo S, Eaimworawuthikul S, Thiennimitr P, Pongchaidecha A, Lungkaphin A, Pratchayasakul W, Chattipakorn SC, Chattipakorn N (2018) Chronic treatment with prebiotics, probiotics and synbiotics attenuated cardiac dysfunction by improving cardiac mitochondrial dysfunction in male obese insulin-resistant rats. Eur J Nutr 57(6):2091\u20132104. https:\/\/doi.org\/10.1007\/s00394-017-1482-3","journal-title":"Eur J Nutr"},{"issue":"3","key":"10220_CR124","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2017.11.024","volume":"71","author":"JT Thackeray","year":"2018","unstructured":"Thackeray JT, Hupe HC, Wang Y, Bankstahl JP, Berding G, Ross TL, Bauersachs J, Wollert KC, Bengel FM (2018) Myocardial inflammation predicts remodeling and neuroinflammation after myocardial infarction. J Am Coll Cardiol 71(3):263\u2013275. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.024","journal-title":"J Am Coll Cardiol"},{"key":"10220_CR125","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fphar.2018.00176","volume":"9","author":"J Qi","year":"2018","unstructured":"Qi J, Wang F, Yang P, Wang X, Xu R, Chen J, Yuan Y, Lu Z, Duan J (2018) Mitochondrial fission Is required for angiotensin II-induced cardiomyocyte apoptosis mediated by a Sirt1-p53 signaling pathway. Front Pharmacol 9:176. https:\/\/doi.org\/10.3389\/fphar.2018.00176","journal-title":"Front Pharmacol"},{"issue":"1","key":"10220_CR126","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2008.01.043","volume":"134","author":"L Lu","year":"2009","unstructured":"Lu L, Wu W, Yan J, Li X, Yu H, Yu X (2009) Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int J Cardiol 134(1):82\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2008.01.043","journal-title":"Int J Cardiol"},{"issue":"10","key":"10220_CR127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163158","volume":"11","author":"VR Mali","year":"2016","unstructured":"Mali VR, Pan G, Deshpande M, Thandavarayan RA, Xu J, Yang XP, Palaniyandi SS (2016) Cardiac mitochondrial respiratory dysfunction and tissue damage in chronic hyperglycemia correlate with reduced aldehyde dehydrogenase-2 activity. PLoS ONE 11(10):e0163158. https:\/\/doi.org\/10.1371\/journal.pone.0163158","journal-title":"PLoS ONE"},{"issue":"9","key":"10220_CR128","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1194\/jlr.RA119000141","volume":"60","author":"HC Tseng","year":"2019","unstructured":"Tseng HC, Lin CC, Hsiao LD, Yang CM (2019) Lysophosphatidylcholine-induced mitochondrial fission contributes to collagen production in human cardiac fibroblasts. J Lipid Res 60(9):1573\u20131589. https:\/\/doi.org\/10.1194\/jlr.RA119000141","journal-title":"J Lipid Res"},{"issue":"3","key":"10220_CR129","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCRESAHA.108.175919","volume":"103","author":"T Liu","year":"2008","unstructured":"Liu T, O\u2019Rourke B (2008) Enhancing mitochondrial Ca2+ uptake in myocytes from failing hearts restores energy supply and demand matching. Circ Res 103(3):279\u2013288. https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.175919","journal-title":"Circ Res"},{"issue":"1","key":"10220_CR130","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/CIRCRESAHA.115.303062","volume":"115","author":"T Liu","year":"2014","unstructured":"Liu T, Takimoto E, Dimaano VL, DeMazumder D, Kettlewell S, Smith G, Sidor A, Abraham TP, O\u2019Rourke B (2014) Inhibiting mitochondrial Na+\/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure. Circ Res 115(1):44\u201354. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.303062","journal-title":"Circ Res"},{"issue":"2","key":"10220_CR131","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/cvr\/cvn179","volume":"80","author":"S Wang","year":"2008","unstructured":"Wang S, Peng Q, Zhang J, Liu L (2008) Na+\/H+ exchanger is required for hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain. Cardiovasc Res 80(2):255\u2013262. https:\/\/doi.org\/10.1093\/cvr\/cvn179","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10220_CR132","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1161\/HYPERTENSIONAHA.120.16466","volume":"77","author":"A De Stefano","year":"2021","unstructured":"De Stefano A, Tesauro M, Di Daniele N, Vizioli G, Schinzari F, Cardillo C (2021) Mechanisms of SGLT2 (sodium-glucose transporter type 2) inhibition-induced relaxation in arteries from human visceral adipose tissue. Hypertension 77(2):729\u2013738. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16466","journal-title":"Hypertension"},{"issue":"1","key":"10220_CR133","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","volume":"19","author":"V Spigoni","year":"2020","unstructured":"Spigoni V, Fantuzzi F, Carubbi C, Pozzi G, Masselli E, Gobbi G, Solini A, Bonadonna RC, Dei Cas A (2020) Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovasc Diabetol 19(1):46. https:\/\/doi.org\/10.1186\/s12933-020-01016-5","journal-title":"Cardiovasc Diabetol"},{"key":"10220_CR134","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.expneurol.2014.12.023","volume":"272","author":"HB Chang","year":"2015","unstructured":"Chang HB, Gao X, Nepomuceno R, Hu S, Sun D (2015) Na(+)\/H(+) exchanger in the regulation of platelet activation and paradoxical effects of cariporide. Exp Neurol 272:11\u201316. https:\/\/doi.org\/10.1016\/j.expneurol.2014.12.023","journal-title":"Exp Neurol"},{"key":"10220_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114276","volume":"182","author":"CH Lescano","year":"2020","unstructured":"Lescano CH, Leonardi G, Torres PHP, Amaral TN, de Freitas Filho LH, Antunes E, Vicente CP, Anhe GF, Monica FZ (2020) The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation. Biochem Pharmacol 182:114276. https:\/\/doi.org\/10.1016\/j.bcp.2020.114276","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10220_CR136","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2174\/1871530319666191014110414","volume":"20","author":"H Yaribeygi","year":"2020","unstructured":"Yaribeygi H, Atkin SL, Jamialahmadi T, Sahebkar A (2020) A review on the effects of new anti-diabetic drugs on platelet function. Endocr Metab Immune Disord Drug Targets 20(3):328\u2013334. https:\/\/doi.org\/10.2174\/1871530319666191014110414","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10220_CR137","doi-asserted-by":"publisher","unstructured":"Wichaiyo S, Maiuthed A (2021) Pathological roles of platelets in inflammatory diseases: the emerging targets for new drug development. Pharm Sci Asia 48(5):402\u2013412. https:\/\/doi.org\/10.29090\/psa.2021.05.21.023","DOI":"10.29090\/psa.2021.05.21.023"},{"issue":"22","key":"10220_CR138","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1093\/eurheartj\/ehl305","volume":"27","author":"I Chung","year":"2006","unstructured":"Chung I, Lip GY (2006) Platelets and heart failure. Eur Heart J 27(22):2623\u20132631. https:\/\/doi.org\/10.1093\/eurheartj\/ehl305","journal-title":"Eur Heart J"},{"issue":"2","key":"10220_CR139","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11739-012-0837-2","volume":"9","author":"R Cangemi","year":"2014","unstructured":"Cangemi R, Celestini A, Del Ben M, Pignatelli P, Carnevale R, Proietti M, Calabrese CM, Basili S, Violi F (2014) Role of platelets in NOX2 activation mediated by TNFalpha in heart failure. Intern Emerg Med 9(2):179\u2013185. https:\/\/doi.org\/10.1007\/s11739-012-0837-2","journal-title":"Intern Emerg Med"},{"issue":"1","key":"10220_CR140","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/hrt.2007.115006","volume":"94","author":"C Stumpf","year":"2008","unstructured":"Stumpf C, Lehner C, Raaz D, Yilmaz A, Anger T, Daniel WG, Garlichs CD (2008) Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure. Heart 94(1):65\u201369. https:\/\/doi.org\/10.1136\/hrt.2007.115006","journal-title":"Heart"},{"issue":"12","key":"10220_CR141","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/ncpcardio1364","volume":"5","author":"AJ Ijsselmuiden","year":"2008","unstructured":"Ijsselmuiden AJ, Musters RJ, de Ruiter G, van Heerebeek L, Alderse-Baas F, van Schilfgaarde M, Leyte A, Tangelder GJ, Laarman GJ, Paulus WJ (2008) Circulating white blood cells and platelets amplify oxidative stress in heart failure. Nat Clin Pract Cardiovasc Med 5(12):811\u2013820. https:\/\/doi.org\/10.1038\/ncpcardio1364","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10220_CR142","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/ijms22157976","volume":"22","author":"M Trum","year":"2021","unstructured":"Trum M, Riechel J, Wagner S (2021) Cardioprotection by SGLT2 inhibitors-does it all come down to Na(+)? Int J Mol Sci 22:15. https:\/\/doi.org\/10.3390\/ijms22157976","journal-title":"Int J Mol Sci"},{"key":"10220_CR143","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10079-9","author":"M Nikolic","year":"2021","unstructured":"Nikolic M, Zivkovic V, Jovic JJ, Sretenovic J, Davidovic G, Simovic S, Djokovic D, Muric N, Bolevich S, Jakovljevic V (2021) SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. Heart Fail Rev. https:\/\/doi.org\/10.1007\/s10741-021-10079-9","journal-title":"Heart Fail Rev"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10220-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-022-10220-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10220-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T07:16:30Z","timestamp":1665126990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-022-10220-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":143,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10220"],"URL":"https:\/\/doi.org\/10.1007\/s10741-022-10220-2","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"assertion":[{"value":"2 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}